SCHEMBL25205299

SCHEMBL25205299

CN(C)c1ccc(C(=O)C=Cc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.79
NPC1 O15118 4/20 0.79
RAB9A P51151 4/20 0.79
KMT2A Q03164 3/20 0.79
SMN1; SMN2 Q16637 2/20 0.79
CASP3 P42574 1/20 0.79
CYP1B1 Q16678 1/20 0.79
SENP8 Q96LD8 1/20 0.79
SENP7 Q9BQF6 1/20 0.79
SENP6 Q9GZR1 1/20 0.79
TLR9 Q9NR96 2/20 0.77
CRHBP P24387 1/20 0.77
CRHR2 Q13324 1/20 0.77
MAOB P27338 2/20 0.71
XDH P47989 1/20 0.63
HSD17B3 P37058 1/20 0.62
MEN1 O00255 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9732309 1.00 MAPT (0.79) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL25190978 1.00 MAPT (0.79) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL2911445 0.93 TLR9 (0.87) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL2911444 0.93 TLR9 (0.87) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL482915 0.89 MAPT (1.00) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL482916 0.89 MAPT (1.00) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL3448404 0.89 MAPT (0.88) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4582427 0.89 MAPT (0.88) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL3448406 0.89 MAPT (0.88) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL25200423 0.87 CRHBP (1.00) MAPTNPC1RAB9AKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885NPC1 1378/4885RAB9A 480/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885NPC1 1908/4885RAB9A 1327/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885NPC1 1908/4885RAB9A 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.